氯喹和羟氯喹治疗住院COVID-19患者的疗效：一项荟萃分析。
Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis.
作者信息
Deng Jiawen, Zhou Fangwen, Heybati Kiyan, Ali Saif, Zuo Qi Kang, Hou Wenteng, Dhivagaran Thanansayan, Ramaraju Harikrishnaa Ba, Chang Oswin, Wong Chi Yi, Silver Zachary
机构信息
Faculty of Health Sciences, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada.
Mayo Clinic Alix School of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
出版信息
Future Virol. 2021 Nov. doi: 10.2217/fvl-2021-0119. Epub 2021 Dec 3.
To evaluate the efficacy and safety of hydroxychloroquine/chloroquine, with or without azithromycin, in treating hospitalized COVID-19 patients. Data from randomized and observational studies were included in a random-effects meta-analysis. Primary outcomes included time to negative conversion of SARS-CoV-2 tests, length of stay, mortality, incidence of mechanical ventilation, time to normalization of body temperature, incidence of adverse events and incidence of QT prolongations. Fifty-one studies (n = 61,221) were included. Hydroxychloroquine/chloroquine showed no efficacy in all primary efficacy outcomes, but was associated with increased odds of QT prolongations. Due to a lack of efficacy and increased odds of cardiac adverse events, hydroxychloroquine/chloroquine should not be used for treating hospitalized COVID-19 patients.
评估羟氯喹/氯喹联合或不联合阿奇霉素治疗住院的2019冠状病毒病（COVID-19）患者的疗效和安全性。随机和观察性研究的数据纳入随机效应荟萃分析。主要结局包括严重急性呼吸综合征冠状病毒2（SARS-CoV-2）检测转阴时间、住院时间、死亡率、机械通气发生率、体温恢复正常时间、不良事件发生率和QT间期延长发生率。纳入了51项研究（n = 61221）。羟氯喹/氯喹在所有主要疗效结局中均未显示出疗效，但与QT间期延长几率增加相关。由于缺乏疗效且心脏不良事件几率增加，羟氯喹/氯喹不应被用于治疗住院的COVID-19患者。
Zotero 插件